Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06812052 · ClinicalTrials.gov registry record · Phase 1
Short Course Radiation Treatment for Patients With Primary or Locally Recurrent Retroperitoneal Sarcoma Prior to Surgery
A Phase 1 study of Retroperitoneal Sarcoma, sponsored by Brigham and Women's Hospital.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
- 1
- Study location
NCT06812052: Recruiting Phase 1 study of Retroperitoneal Sarcoma, sponsored by Brigham and Women's Hospital.
NCT06812052 is a Phase 1 study of Retroperitoneal Sarcoma that is actively recruiting participants, run by Brigham and Women's Hospital. The registered enrollment target is 6 participants, below the 415-participant average among 6 other Retroperitoneal Sarcoma trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06812052, a Phase 1 study of Retroperitoneal Sarcoma, is actively recruiting participants, sponsored by Brigham and Women's Hospital.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
- 1
- Study location
Study Summary
To determine the safety of moderately hypofractionated radiation in the treatment of primary and locally recurrent RPS, based on the evaluation of acute radiation-related toxicity profile of each participant (30-day radiation toxicity)
Primary Outcome
Evaluation of acute radiation-related toxicity profile of each participant, specifically nausea, vomiting, diarrhea, and other gastrointestinal (GI) side effects.
Conditions Studied
Interventions
- RADIATION Radiation Therapy
- RADIATION Hypofractionationed Radiation Therapy
Study Locations (1)
Massachusetts
- Brigham and Women's Hospital / Dana Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2025-05-29 |
| Est. Completion | 2026-11 |
| Phase | Phase 1 |
What NCT06812052 shows while recruiting
NCT06812052 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 415-participant average among 6 other Retroperitoneal Sarcoma trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Retroperitoneal Sarcoma appearing as the primary indexed condition, and to 2 interventions - of which Radiation Therapy is the first listed.
NCT06812052 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06812052 about?
NCT06812052 is a clinical study titled "Short Course Radiation Treatment for Patients With Primary or Locally Recurrent Retroperitoneal Sarcoma Prior to Surgery". To determine the safety of moderately hypofractionated radiation in the treatment of primary and locally recurrent RPS, based on the evaluation of acute radiation-related toxicity profile of each participant (30-day radiation toxicity)
What is the current status of trial NCT06812052?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2025-05-29. Estimated completion is 2026-11.
What conditions does trial NCT06812052 study?
This clinical trial studies the following conditions: Retroperitoneal Sarcoma.
What interventions are being tested in trial NCT06812052?
The interventions under investigation include: Radiation Therapy (RADIATION), Hypofractionationed Radiation Therapy (RADIATION).
Who is sponsoring clinical trial NCT06812052?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06812052 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Retroperitoneal Sarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluation of Abemaciclib and Radiation Therapy Before Surgery for the Treatment of High-Risk Adipocytic Retroperitoneal Sarcoma
RECRUITING · Phase 1
-
Proton or Photon RT for Retroperitoneal Sarcomas
RECRUITING · Phase 1
-
Proton-Spatially Fractionated Radiotherapy and Standard Radiation Therapy for the Treatment of Newly Diagnosed Retroperitoneal Soft Tissue Sarcoma
RECRUITING · Phase 1
-
Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma
RECRUITING · Phase 3
-
REtroperitoneal SArcoma Registry: an International Prospective Initiative
RECRUITING
-
Repeat or Single Quadratus Lumborum Block for the Reduction of Opioid Prescriptions After Surgery in Retroperitoneal Sarcoma Patients ("RESQU-SARC" Trial)
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI